Quantcast

Questcor to Report First Quarter 2011 Earnings and Conduct Conference Call on April 26, 2011

April 18, 2011

ANAHEIM, Calif., April 18, 2011 /PRNewswire-FirstCall/ — Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it will release first quarter 2011 financial results on Tuesday, April 26, 2011 after the close of the U.S. financial markets. The Company will host a conference call and webcast on Tuesday, April 26, 2011 at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss results and highlights of the first quarter, as well as current corporate developments.


    Conference call details:
    Date:               Tuesday, April 26, 2011
    Time:               4:30 p.m. ET
    Dial-in (U.S.):     877-941-1465
    Dial-in
     (International):   480-629-9678
    Web cast:           www.questcor.com

    To access an audio replay of the call:

    Replay (U.S.):      800-406-7325
    Replay
     (International):   303-590-3030
    Replay Passcode:                                   4434709

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions. Questcor’s primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of infantile spasms in children under two years of age and the treatment of nephrotic syndrome. Specifically with respect to nephrotic syndrome, the FDA has approved Acthar to “induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus.” Questcor is also exploring the possibility of developing markets for other on-label indications and pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. Questcor also markets Doral®( )(quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. For more information, please visit www.questcor.com.

SOURCE Questcor Pharmaceuticals, Inc.


Source: newswire



comments powered by Disqus